

Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)

**Regd. Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills,
Hyderabad - 500033, Telangana**

Tel No.: +91 9391139986 / 22-4111 4777 | CIN: L99999TS1985PLC196357

Website: www.sequent.in | Email: investorrelations@sequent.in

POSTAL BALLOT NOTICE

Dear Member(s),

Notice is hereby given pursuant to Section 110 and other applicable provisions, if any, of the Companies Act, 2013 (the 'Act'), read with Rule 20 and 22 of the Companies (Management and Administration) Rules, 2014 (the 'Rules') (including any statutory amendment(s) or modification(s) or re-enactment(s) thereof for the time being in force) read with General Circular Nos. 14/2020 dated 08th April 2020, 17/2020 dated 13th April 2020 and subsequent circulars issued in this regard, the latest being General Circular No. 03/2025 dated 22nd September 2025 issued by the Ministry of Corporate Affairs, Government of India (the 'MCA Circulars'), Secretarial Standards 2 issued by the Institute of Company Secretaries of India on General Meetings and pursuant to other applicable laws and regulations, the proposed resolutions along with the explanatory statement setting out the material facts are appended below for seeking consent of the Members of Viyash Scientific Limited (the 'Company') through postal ballot by remote voting process.

In compliance with Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), provisions of Section 108 and 110 of the Act read with the Rules and the MCA Circulars, the Company has extended remote e-voting facility to its Members, to enable them to cast their votes electronically instead of submitting postal ballot form. Accordingly, physical copy of the Postal Ballot Notice along with postal ballot forms and pre-paid business reply envelope will not be sent to the Members for this Postal Ballot and Members are required to communicate their assent or dissent through the remote e-voting system only. The detailed instructions for remote e-voting forms part of this Postal Ballot Notice.

The remote e-voting schedule is given in the table below:

Cut-off date for reckoning voting rights for e-voting	Commencement of e-voting (Start date)	Close of e-voting (End date)	Results announcement date
Friday, February 06, 2026	Wednesday, February 11, 2026, at 9:00 AM (IST)	Thursday, March 12, 2026 at 5:00 PM (IST)	On or before, Monday, March 16, 2026

The Company has engaged the services of National Securities Depository Limited ('NSDL' or 'Service Provider'), for providing remote e-voting facility to the Members.

During this period, Members of the Company, holding shares either in physical form or in dematerialized form, as on the Cut-off date, may cast their vote electronically in lieu of voting by physical ballot. The e-voting module shall be disabled by NSDL for voting after the End date and time. Please read and follow the instructions on e-voting enumerated in the notes to this Postal Ballot Notice.

The proposed resolution and an explanatory statement pursuant to Section 102 of the Act read with Rules and MCA Circulars is appended to this Postal Ballot Notice.

The Postal Ballot Notice shall also be placed on the website of the Company at www.sequent.in and on the website of NSDL at www.evoting.nsdl.com. The Notice can also be accessed from the website of the Stock Exchanges i.e. BSE Limited ('BSE') and National Stock Exchange of India Limited ('NSE') at www.bseindia.com and www.nseindia.com respectively.

The Board of Directors of the Company has appointed M/s. Nishant Darak and Associates, Practicing Company Secretaries represented by Mr. Nishant Darak (ACS 71502, CP No.26646), as the Scrutinizer for conducting the Postal Ballot/ e-voting process. The Company has received consent from M/s. Nishant Darak and Associates conveying their acceptance to act as Scrutinizer for the said Postal Ballot.

The Scrutinizer will submit his report to the Chairperson or any person authorised by the Chairperson of the Company after completion of the remote e-voting process. The e-voting results will be declared on or before Monday, March 16, 2026. The declaration of the results as stated above shall be treated as declaration of results at a Meeting of the Members as per the provisions of the Act and applicable Rules framed thereunder. The e-voting results declared along with the Scrutinizer's Report will be communicated to the Stock Exchanges, i.e. BSE and NSE where the Equity Shares of the Company are listed. Additionally, the results will also be placed on the website of the Company at www.sequent.in and the website of NSDL at i.e. www.evoting.nsdl.com

The resolution with requisite majority shall be deemed to have been passed on Thursday, March 12, 2026 at 5:00 PM (IST) i.e. last date of e-voting.

SPECIAL BUSINESS:

Item No. 1: Appointment and remuneration of Dr. Haribabu Bodepudi (DIN: 01119687) as Managing Director and Group CEO of the Company for a period of two years.

To consider and if thought fit, to pass, the following as a **Special Resolution**:

“RESOLVED THAT pursuant to the provisions of Sections 196, 197, 198 and 203, read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 read with the relevant rules made thereunder (including any amendment(s), modifications(s) or variation(s) thereto) ('Act'), applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, the articles of association of Viyash Scientific Limited ('Company'), and subject to such other consents, approvals, permissions and sanctions as may be necessary, and pursuant to the recommendation made by Nomination and Remuneration Committee and approval of the Board of Directors of the Company, consent of the Members of the Company, be and is hereby accorded for appointment of Dr. Haribabu Bodepudi (DIN: 01119687) as the Managing Director and Group CEO of the Company, for a period of 2 years w.e.f. December 16, 2025 to December 15, 2027, liable to retire by rotation, on the terms and conditions of appointment and remuneration as set out in the explanatory statement annexed to the Notice with liberty and power to the Board of Directors to grant increments and to alter and vary from time to time the terms and conditions of the said appointment, subject to the same being within the limits set out in the explanatory statement and as specified under the Act.

RESOLVED FURTHER THAT in case of no profits or inadequacy of profits, such remuneration (comprising salary, perquisites and benefits), as approved hereinabove, be paid as minimum remuneration in accordance with Section 197 read with Schedule V of the Act.

RESOLVED FURTHER THAT for the purpose of giving effect to this resolution, the directors and the Company Secretary be and are hereby severally authorized to do all such acts, deeds, filings, matters and things, including for obtaining any approvals, statutory, contractual or otherwise, in relation to the above, and to sign and submit necessary documents, deeds, instruments, letters with the registrar of companies (if required) for and on behalf of the Company, in relation to the foregoing resolution, as may be required under applicable law, and as any of them may in their absolute discretion deem necessary proper or desirable and to settle any questions or doubts that may arise in this regard.

RESOLVED FURTHER THAT the directors and the Company Secretary of the Company be and are hereby severally authorized to certify a copy of this resolution and issue the same to any relevant person(s)/authorities as and when required.

RESOLVED FURTHER THAT all acts, deeds, things and matters performed by the authorised representatives of the Company within the authority provided under this resolution shall be valid, enforceable and binding on the Company.”

Item No. 2: Grant of options of more than 1% (one per cent) of the issued capital of the Company to an identified employee in 1 (one) year.

To consider and if thought fit, to pass, the following as a **Special Resolution**:

“**RESOLVED THAT** pursuant to the provisions of Section 62(1)(b) and other applicable provisions, if any, of the Companies Act, 2013 read with Rule 12 of the Companies (Share Capital and Debentures) Rules, 2014, Regulation 6(3)(d) of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, and other provisions of applicable law for the time being in force and as may be modified from time to time, the Memorandum of Association and Articles of Association of the Company, provisions contained in Vijash Scientific Limited Employee Stock Option Scheme 2026 (‘ESOP Scheme’), and subject to such other consents, approvals, permissions and sanctions as may be necessary, and pursuant to the recommendation of the Nomination and Remuneration Committee and the Board of Directors of the Company, the consent and approval of the Members of the Company be and is hereby accorded for the grant of such number of stock options, to Dr. Haribabu Bodepudi, Managing Director and Group Chief Executive Officer of the Company, in one or more tranches, under the ESOP Scheme, in accordance with the terms thereof, during any one year, which may be equal to or exceed 1% (one percent) of the issued capital of the Company (excluding outstanding warrants and conversions), at the time of grant of options.

RESOLVED FURTHER THAT for the purpose of giving effect to this resolution, the Board of Directors (including the Nomination and Remuneration Committee and/or such other committee as may be decided by the Board), and the Company Secretary be and are hereby severally authorized to do all such acts, deeds, filings, matters and things, including for obtaining any approvals, statutory, contractual or otherwise, in relation to the above, and to sign and submit necessary documents, deeds, instruments, letters with the registrar of companies (if required) for and on behalf of the Company, in relation to the foregoing resolution, as may be required under applicable law, and as any of them may in their absolute discretion deem necessary proper or desirable and to settle any questions or doubts that may arise in this regard.

RESOLVED FURTHER THAT the directors and the Company Secretary of the Company be and are hereby severally authorized to certify a copy of this resolution and issue the same to any relevant person(s)/authorities as and when required.

RESOLVED FURTHER THAT all acts, deeds, things and matters performed by the authorised representatives of the Company within the authority provided under this resolution shall be valid, enforceable and binding on the Company.”

Item No. 3: Appointment of Mr. Rajaram Narayanan (DIN: 02977405) as a Whole-time Director.

To consider and if thought fit, to pass, the following as a **Special Resolution**:

“**RESOLVED THAT** in furtherance of the approval by the Members through postal ballot on April 9, 2022, at the thirty ninth Annual General Meeting of the Company on September 17, 2024, and at the fortieth Annual General Meeting of the Company on August 08, 2025, and pursuant to the provisions of Sections 196, 197, 198 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 read with the relevant rules made thereunder (including any amendment(s), modifications(s) or variation(s) thereto) (‘Act’), applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any amendment(s), modifications(s) or variation(s) thereto), the Articles of Association of the Company, and subject to such other consents, approvals, permissions and sanctions as may be necessary, and pursuant to the recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors of the Company, consent of the Members of the Company, be and is hereby accorded for appointment of Mr. Rajaram Narayanan (DIN: 02977405) as the Whole-time Director, liable to retire by rotation and re-designating him as CEO – Animal Health Business of the Company, for his remaining tenure i.e. till April 10, 2027, on the terms and conditions as approved by the Members at the Annual General Meeting held on August 8, 2025,

with liberty and power to the Board of Directors to grant increments and to alter and vary from time to time the terms and conditions of the said appointment, subject to the same being within the limits set out in the explanatory statement and as specified under the Act.

RESOLVED FURTHER THAT in case of no profits or inadequacy of profits, such remuneration (comprising salary, perquisites and benefits), as approved hereinabove, be paid as minimum remuneration in accordance with Section 197 read with Schedule V of the Act.

RESOLVED FURTHER THAT for the purpose of giving effect to this resolution, the directors and the Company Secretary be and are hereby severally authorized to do all such acts, deeds, filings, matters and things, including for obtaining any approvals, statutory, contractual or otherwise, in relation to the above, and to sign and submit necessary documents, deeds, instruments, letters with the registrar of companies (if required) for and on behalf of the Company, in relation to the foregoing resolution, as may be required under applicable law, and as any of them may in their absolute discretion deem necessary proper or desirable and to settle any questions or doubts that may arise in this regard.

RESOLVED FURTHER THAT the directors and the Company Secretary of the Company be and are hereby severally authorised to certify a copy of this resolution and issue the same to any relevant person(s)/authorities as and when required.

RESOLVED FURTHER THAT all acts, deeds, things and matters performed by the authorised representatives of the Company within the authority provided under this resolution shall be valid, enforceable and binding on the Company."

Item No. 4: Appointment of Mr. Srinivas Vasireddy (DIN: 09771153) as Whole time Director (Executive) of the Company for a period of two years.

To consider and if thought fit, to pass, the following as a **Special Resolution**:

"RESOLVED THAT pursuant to the provisions of Sections 149, 152, 196, 197, 198 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013 read with the relevant rules made thereunder (including any amendment(s), modifications(s) or variation(s) thereto) ('Act'), applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any amendment(s), modifications(s) or variation(s) thereto), the articles of Association of the Company, and subject to such other consents, approvals, permissions and sanctions as may be necessary, and pursuant to the recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors of the Company, consent of the Members of the Company, be and is hereby accorded for appointment of Mr. Srinivas Vasireddy (DIN: 09771153) as a Whole-time Director, designated as an Executive Director, liable to retire by rotation, for a period of 2 years w.e.f. December 16, 2025 to December 15, 2027, on the terms and conditions including remuneration as set out in the explanatory statement annexed to the Notice, with liberty and power to the Board of Directors to grant increments and to alter and vary from time to time the terms and conditions of the said appointment, subject to the same being within the limits set out in the explanatory statement and as specified under the Act.

RESOLVED FURTHER THAT in case of inadequacy of profits, such remuneration (comprising salary, perquisites and benefits), as approved hereinabove, be paid as minimum remuneration in accordance with Section 197 read with Schedule V of the Act.

RESOLVED FURTHER THAT for the purpose of giving effect to this Resolution, the directors and the Company Secretary be and are hereby severally authorized to do all such acts, deeds, filings, matters and things, including for obtaining any approvals, statutory, contractual or otherwise, in relation to the above, and to sign and submit necessary documents, deeds, instruments, letters with the registrar of companies (if required) for and on behalf of the Company, in relation to the foregoing resolution, as may be required under applicable law, and as any of them may in their absolute discretion deem necessary proper or desirable and to settle any questions or doubts that may arise in this regard.

RESOLVED FURTHER THAT the directors and the Company Secretary of the Company be and are hereby severally authorized to certify a copy of this resolution and issue the same to any relevant person(s)/authorities as and when required.

RESOLVED FURTHER THAT all acts, deeds, things and matters performed by the authorized representatives of the Company within the authority provided under this resolution shall be valid, enforceable and binding on the Company.”

By order of the Board of Directors of
Viyash Scientific Limited
(Formerly Known as Sequent Scientific Limited)

Sd/-

Yoshita Vora
Company Secretary & Compliance Officer
Membership No.: ACS 22220

Place: Hyderabad

Date : February 5, 2026

NOTES

1. Explanatory Statement as required under Section 102 of the Companies Act, 2013 ("the Act") and other applicable provisions of the Act read with the Rules, in respect of the resolutions proposed to be passed is annexed to this Notice.
2. In compliance with the MCA Circulars, the Postal Ballot Notice along with the instructions regarding Remote e-voting is being sent by electronic mode only to those Members whose names appear in the Register of Members/ List of Beneficial Owners maintained by the Company / Depositories as at close of business hours on Friday , February 06, 2026 ('Cut-off date'), and whose e-mail IDs are registered with the Depository Participants (DPs) or with the Company or its Registrar and Transfer Agent as on the Cut-off date. Newspaper advertisement regarding dispatch of Postal Ballot Notice shall be published as per statutory requirements.
3. The voting rights of the Members shall be in proportion to their share in the Paid-up Equity Share Capital of the Company as on the **cut-off date mentioned in Note 8 herein below**.
4. A person who is not a Member as on the cut-off date should treat this notice for information purpose only.
5. In compliance of the provisions of Sections 108 and 110 of the Act and Rules framed thereunder and Regulation 44 of the Listing Regulations and the MCA Circulars, the Company is pleased to provide its Members the facility to exercise their right to vote electronically on the Postal Ballot through the Electronic Voting (e-voting) Services provided by National Securities Depository Limited ('NSDL'). The instructions for electronic voting are annexed to this Postal Ballot Notice.
6. During the voting period, Members can login to NSDL's e-voting platform any number of times till they have voted on the Resolution. Once the vote on a Resolution is cast by a Member, whether partially or otherwise, the Member shall not be allowed to change it subsequently or cast the vote again.
7. Resolution passed by the Members through Postal Ballot are deemed to have been passed effectively at a General Meeting of the Members on the last date specified by the Company for remote e-voting i.e. Thursday, March 12, 2026 at 5:00 PM (IST).
8. **E-voting schedule:**
The details are as under:

Cut-off date for reckoning voting rights for e-voting	Commencement of e-voting (Start date)	Close of e-voting (End date)	Results announcement date
Friday, February 06, 2026	Wednesday, February 11, 2026, at 9:00 AM (IST)	Thursday, March 12, 2026 at 5:00 PM (IST)	On or before, Monday, March 16, 2026

During this period, shareholders of the Company, holding shares either in physical form or in dematerialized form, as on the Cut-off date, may cast their vote electronically in lieu of voting by physical ballot. The e-voting module shall be disabled by NSDL for voting after the end of the voting time.

9. In accordance with Section 110 of the Act and Rules 20 and 22 of the Companies (Management and Administration) Rules, 2014 read with the MCA Circulars, physical copies of the Postal Ballot Notice will not be circulated and also the Company will not be under any obligation to provide physical copies upon specific request of any Member(s).

The Postal Ballot Notice is being sent only through electronic mode to those Members whose names appear in the Register of Members of the Company or in the Register of Beneficial Owners maintained by the Depositories, as on the cut-off date mentioned in **Note 8** above, and who have registered their e-mail addresses with the Company or with the Depositories.

Therefore, Members are requested and encouraged to register/ update their email addresses, with their Depository Participant (in case of Shares held in dematerialised form) or with KFin Technologies Limited, our Registrar and Share Transfer Agents (RTA) (in case of Shares held in physical form).

Members holding shares in dematerialized mode are requested to register/ update their email addresses with their Depository Participant(s). The Company and RTA shall co-ordinate with National Securities Depository Limited (NSDL) and provide the login credentials to the above-mentioned Members, subject to receipt of the required documents and information from the Members.

The Postal Ballot Notice is also being uploaded on the website of the Company at www.sequent.in, and on the website of stock exchanges at BSE Limited (www.bseindia.com) and at National Stock Exchange of India Limited (www.nseindia.com) and on the website of our Remote e-voting agency i.e. NSDL e-voting website at www.evoting.nsd.com.

10. Documents referred to in the Postal Ballot Notice or explanatory statement will be available for inspection by the Members, in accordance with the provisions of the Act, without any fee, from the date of circulation of the Postal Ballot Notice up to the closure of the e-voting ('e-voting period'). Members desirous of inspecting the documents referred to in the Notice or explanatory statement may send their requests in advance to investorrelations@sequent.in from their registered e-mail addresses mentioning their name(s), folio numbers/DP ID and Client ID, between e-voting period.
11. Members of the Company as on the Cut-off date (including those Members who may not have received this Notice due to non-registration of their e-mail addresses with the Company/RTA/Depositories) shall be entitled to vote in relation to the above resolutions in accordance with the process specified in this Postal Ballot Notice.
12. The result of voting on the Resolutions will be declared on or before Monday, March 16, 2026 and will also be displayed on the website of the Company (www.sequent.in) besides being communicated to the Stock Exchanges.
13. E-voting instructions are appended to this Notice in **Appendix 1**.

Appendix 1

The procedure for e-voting is as under:

The way to vote electronically on NSDL e-Voting system consists of “Two Steps” which are mentioned below:

Step 1: Access to NSDL e-Voting system

A) Login method for e-Voting for Individual shareholders holding securities in demat mode in terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with NSDL.	<ol style="list-style-type: none"> 1. For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID, 8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period. 2. Existing IDeAS user can visit the e-Services website of NSDL Viz. https://eservices.nsdl.com either on a Personal Computer or on a mobile. On the e-Services home page click on the “Beneficial Owner” icon under “Login” which is available under ‘IDeAS’ section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on “Access to e-Voting” under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period. 3. If you are not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select “Register Online for IDeAS Portal” or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 4. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period. 5. Shareholders/Members can also download NSDL Mobile App “NSDL Speede” facility by scanning the QR code mentioned below for seamless voting experience.

	<p style="text-align: center;">NSDL Mobile App is available on</p> <div style="display: flex; justify-content: space-around; align-items: center;">  App Store  Google Play </div> <div style="display: flex; justify-content: space-around; align-items: center; margin-top: 10px;">   </div>
<p>Individual Shareholders holding securities in demat mode with CDSL</p>	<ol style="list-style-type: none"> 1. Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login Easi / Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & New System Myeasi Tab and then user your existing my easi username & password. 2. After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. 3. If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option. 4. Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from an e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.
<p>Individual Shareholders (holding securities in demat mode) login through their depository participants</p>	<p>You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period.</p>

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at or call at 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800-21-09911

B) Login Method for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.

How to Log-in to NSDL e-Voting website?

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.

Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.

4. Your User ID details are given below:

Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical	Your User ID is:
a) For Members who hold shares in demat account with NSDL.	8 Character DP ID followed by 8 Digit Client ID For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.
b) For Members who hold shares in demat account with CDSL.	16 Digit Beneficiary ID For example if your Beneficiary ID is 12***** then your user ID is 12*****.
c) For Members holding shares in Physical Form.	EVEN Number followed by Folio Number registered with the company For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001***

5. Password details for shareholders other than Individual shareholders are given below:

- a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
- b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.

- c) How to retrieve your 'initial password'?
 - a) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
 - b) If your email ID is not registered, please follow steps mentioned below in process for those shareholders whose email ids are not registered
6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:
 - a) Click on "Forgot User Details/Password?"(If you are holding shares in your demat account with NSDL or CDSL) option available on www.evoting.nsdl.com.
 - b) Physical User Reset Password?" (If you are holding shares in physical mode) option available on www.evoting.nsdl.com.
 - c) If you are still unable to get the password by aforesaid two options, you can send a request at evoting@nsdl.com mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
 - d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
8. Now, you will have to click on "Login" button.
9. After you click on the "Login" button, Home page of e-Voting will open.

Step 2: Cast your vote electronically on NSDL e-Voting system.

How to cast your vote electronically on NSDL e-Voting system?

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle.
2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period.
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.
5. Upon confirmation, the message "Vote cast successfully" will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

General Guidelines for shareholders

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPGFormat) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to nnconsultantsco1@gmail.com with a copy marked to evoting@nsdl.com. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) can also upload their Board Resolution / Power of Attorney / Authority Letter etc. by clicking on "**Upload Board Resolution / Authority Letter**" displayed under "**e-Voting**" tab in their login.
2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the

correct password. In such an event, you will need to go through the “[Forgot User Details/Password?](#)” or “[Physical User Reset Password?](#)” option available on www.evoting.nsdl.com to reset the password.

3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of www.evoting.nsdl.com or call on : 022 - 4886 7000 or send a request to Veena Suvarna at evoting@nsdl.com

Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:

For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self-attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to investorrelations@sequent.in

2. For Demat shareholders -, Please update your email id & mobile no. with your respective Depository Participant (DP)

3. For Individual Demat shareholders – Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.

If you have any queries or issues regarding e-Voting from the NSDL e-Voting System, you can write an email to evoting@nsdl.com or contact at toll free no. 022 - 4886 7000

All grievances connected with the facility for voting by electronic means may be addressed to Ms. Veena Suvarna designated person of National Securities Depository Limited, at 3rd Floor, Naman Chamber, Plot C-32, G-Block, Bandra Kurla Complex, Bandra East, Mumbai, Maharashtra - 400 051 or send an email to evoting@nsdl.com or call at toll free no. 022 - 4886 7000.

User ID for Shareholders holding shares in Physical Form (i.e. Share Certificate): Your User ID is Event No + Folio Number registered with the Company.

Individual Shareholders holding securities in demat mode with NSDL/ CDSL has forgotten the password:

Shareholders who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at above mentioned depository/ depository participant’s website.

- It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- For shareholders/ members holding shares in physical form, the details can be used only for voting on the resolutions contained in this Notice.
- During the voting period, shareholders/ members can login any number of time till they have voted on the resolution(s) for a particular “Event”.

General instructions for shareholders who have not registered their E-mail ID/KYC:

1. Shareholders holding shares in Physical Mode: They can update their KYC details by downloading forms from this link <https://sequent.in/investor-relation/shareholder-information> and submit the hardcopy to the Registrar & Share Transfer Agent (“RTA”)- KFin Technologies Ltd. if not already submitted.

Link: <https://www.kfintech.com/contact-us/>

Address: Selenium Building, Tower-B, Plot No 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddi, Telangana, India - 500 032.

Email ID: einward.ris@kfintech.

2. Shareholders holding shares in Dematerialized Mode: Such Shareholders are requested to register their e-mail ID with the relevant Depository Participant(s).

Explanatory Statement pursuant to Section 102 of the Companies Act, 2013

The following Explanatory Statement sets out all the material facts relating to the Special businesses mentioned under Item Nos. 1 to 4 of the accompanying Postal Ballot Notice dated **February 5, 2026**.

Item No. 1: Appointment and remuneration of Dr. Haribabu Bodepudi (DIN: 01119687) as Managing Director and Group CEO of the Company for a period of two years.

The Board of Directors ('Board'), based on the recommendation of the Nomination and Remuneration Committee ('NRC'), at its meeting held on December 16, 2025, has appointed Dr. Haribabu Bodepudi (DIN: 01119687) as Managing Director and Group Chief Executive Officer (Executive, Non-Independent) of the Company liable to retire by rotation w.e.f. December 16, 2025, to December 15, 2027, subject to the approval of the Members.

Dr. Haribabu Bodepudi was appointed as a Non-Executive Director of the Company with effect from August 07, 2023, pursuant to approval of Members at the Thirty-Eighth Annual General Meeting ('AGM') of the Company held on August 30, 2023.

In view of the proposed merger of Viyash Life Sciences Private Limited and its group companies with the Company, at its meeting held on August 08, 2025, the Board considered and approved the proposed changes in the management structure as a strategic step towards strengthening alignment across the businesses and accelerating the realization of potential synergies post the merger. Following effectiveness of the merger, the Board, upon recommendation of the NRC, has appointed Dr. Haribabu Bodepudi, as the Managing Director and Group Chief Executive Officer of the combined entity. In compliance with the provisions of Sections 196 and 197 read with Schedule V and other applicable provisions of the Companies Act, 2013 ('Act'), the terms of appointment and remuneration of Dr. Haribabu Bodepudi as provided in this Notice, are placed before the Members for their approval.

The Company has received the following from Dr. Haribabu Bodepudi:

- (i) the consent in writing to act as an Managing Director and Group CEO of the Company.
- (ii) intimation that he is not disqualified under section 164(2) of the Act or debarred pursuant to any order of SEBI, Ministry of Corporate Affairs or any such other Authority.
- (iii) disclosure of interest in other entities in terms of Section 184(1) of the Act.

The Company has received a notice from a Member, under Section 160 of the Act, proposing candidature of Dr. Haribabu Bodepudi as Managing Director & Group CEO.

The Members are informed that the Board at its meeting held on December 16, 2025, had pursuant to the recommendation of the NRC, approved the remuneration payable to Dr. Haribabu Bodepudi, as the Managing Director and Group CEO of the Company for the period from December 16, 2025, to December 15, 2027, as detailed below:

Sr. No.	Particulars	Amount per annum (in INR)
1	Basic Salary (1)	3,30,18,870
2	Other allowances (2)	3,30,18,870
3	Fixed remuneration (1+2)	6,60,37,740
4	Variable pay (Performance bonus)	Upto 86% of Fixed CTC
6	Retirals	39,62,260
7	Other benefits (Company car for business use, Housing/ HRA, Leave encashment, Insurance Medical, Reimbursements etc.)	As per Company's Policy
8.	Employee Stock Option Plan	As may be determined by the NRC and Board in accordance with the Viyash Scientific Limited Employee Stock Option Scheme 2026.

The above remuneration shall be subject to an annual increment of up to 20% of his total remuneration, based on the recommendation of the NRC and approval of the Board, in accordance with the agreed performance criteria.

Further, Dr. Haribabu Bodepudi shall not be entitled to sitting fees for attending meetings of the Board of the Company or any committee(s) thereof.

The proposed remuneration for Dr. Haribabu Bodepudi as the Managing Director and Group CEO of the Company has been set based on a benchmarking process against a peer group of leading and well-governed companies in the industry. The remuneration structure is designed to align with market standards and ensure competitiveness.

Additional information in respect of Dr. Haribabu Bodepudi, pursuant to Regulation 36 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') and the Secretarial Standards on General Meetings ('Secretarial Standards – 2') issued by the Institute of Company Secretaries of India, is provided in '**Annexure A**' and forms an integral part of this Notice. Further, disclosure under Schedule V of the Act is set out in '**Annexure B**' to this Notice. Dr. Haribabu Bodepudi satisfies all the conditions set out in Part-I of Schedule V and Section 196(3) of the Act for being eligible for this appointment.

The other terms and conditions of appointment are as set out in the employment agreement executed with Dr. Haribabu Bodepudi, which shall be available for inspection by the Members in accordance with the provisions of the Act.

The Company has not committed any default in payment of dues to any bank or public financial institution or non-convertible debenture holders or any other secured creditor, if any.

Given the expertise, knowledge and experience of Dr. Haribabu Bodepudi, the Board based on the recommendation of the NRC, proposes his appointment as Managing Director & Group CEO of the Company on the terms and conditions and remuneration as set out above, and recommends the Special Resolution set out in **Item no. 1** of the Notice for approval of the Members.

Except Dr. Haribabu Bodepudi and/or his relatives, none of the other Directors, Key Managerial Personnel or their relatives are concerned or interested in this Resolution.

Item No. 2: Grant of options of more than 1% (one per cent) of the issued capital of the Company to an identified employee in 1 (one) year.

The Company is in the process of appointing Dr. Haribabu Bodepudi as the Managing Director and Group Chief Executive Officer of the Company and the approval of the shareholders for his appointment and remuneration is being sought under Item No. 1 of this Notice.

Considering Dr. Haribabu's experience and expertise in the healthcare industry, and the scale of business and the responsibilities proposed to be allocated to him, the Board based on the recommendation of the NRC, at their respective Meetings held on February 05, 2026, recommended, as part of the remuneration package, to grant stock options to Dr. Haribabu, during any one year, which may be equal to or exceed 1% of the issued capital of the Company (excluding outstanding warrants and conversions) at the time of grant. As part of the remuneration package, Dr. Haribabu will be eligible for up to 96,25,000 stock options ('Options'), convertible into equivalent number of equity shares of INR 2/- each of the Company, at an exercise price per share and other terms as may be determined by the NRC in accordance with the terms of the Viyash Scientific Limited Employee Stock Option Scheme 2026.

In terms of Regulation 6(3)(d) of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, a separate resolution is required to be passed by Members if it is intended to grant options to identified employees, during any one year, equal to or exceeding one per cent of the issued capital (excluding outstanding warrants and conversions) of the company at the time of grant of options.

To enable grant of such Options, the Board is seeking approval of the Members of the Company as per the requirement under the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

The Company has not committed any default in payment of dues to any bank or public financial institution or non-convertible debenture holders or any other secured creditor, if any.

Given the expertise, knowledge and experience of Dr. Haribabu Bodepudi, the Board based on the recommendation of the NRC, proposes the grant of the Options to him as set out above, and recommends the Special Resolution set out in **Item no. 2** of the Notice for approval of the Members.

Except Dr. Haribabu Bodepudi and/or his relatives, none of the other Directors, Key Managerial Personnel or their relatives are concerned or interested in this Resolution.

Item No. 3: Appointment of Mr. Rajaram Narayanan (DIN: 02977405) as a Whole-time Director.

The Board, based on the recommendation of the NRC, at its meeting held on December 16, 2025, approved the appointment of Mr. Rajaram Narayanan (DIN: 02977405) as a Whole-time Director (Executive, Non-independent) of the Company w.e.f. December 16, 2025, liable to retire by rotation, subject to the approval of the Members of the Company.

The Board, based on the recommendation of NRC, at its meeting held on January 14, 2022, had appointed Mr. Rajaram Narayanan (DIN: 02977405) as Managing Director and Chief Executive Officer of the Company for a period of 5 years w.e.f. April 11, 2022. The Members of the Company gave their consent to same via special resolution passed by postal ballot on April 09, 2022 (i.e. the last date of e-voting).

In view of the proposed merger of Viyash Life Sciences Private Limited and its group companies with the Company, at its meeting held on August 08, 2025, the Board considered and approved the proposed changes in the management structure as a strategic step towards strengthening alignment across the businesses and accelerating the realization of potential synergies post the merger. Following the effectiveness of the merger scheme and the resulting organizational restructuring, the Board, upon recommendation of the NRC, proposed that Mr. Rajaram Narayanan, shall transition to the role of Whole-time Director and Chief Executive Officer – Animal Health business.

The Company has received the following from Mr. Rajaram Narayanan:

- (i) the consent in writing to act as an Executive Director of the Company.
- (ii) intimation that he is not disqualified under section 164(2) of the Act or debarred pursuant to any order of SEBI, Ministry of Corporate Affairs or any such other Authority.
- (iii) disclosure of interest in other entities in terms of Section 184(1) of the Act.

The Company has received a notice from a Member, under Section 160 of the Act, proposing candidature of Mr. Rajaram Narayanan as Whole time Director.

The terms and conditions governing Mr. Rajaram's remuneration shall continue to remain in force without any alteration and shall be as previously approved by the Members at the Annual General Meeting held on August 8, 2025, and shall also be available for inspection at the registered office of the Company in accordance with the provisions of the Act. For reference, the remuneration terms approved by the Members for Mr. Rajaram are available at [Sequent Annual-Report-FY-2024-25](#).

Further, Mr. Rajaram shall not be entitled to sitting fees for attending meetings of the Board of Directors of the Company or any Committee(s) thereof.

Additional information in respect of Mr. Rajaram Narayanan, pursuant to Regulation 36 of the SEBI Listing Regulations and the Secretarial Standards – 2 issued by the Institute of Company Secretaries of India, is provided in '**Annexure A**' and forms an integral part of this Notice. Further, disclosure under Schedule V of the Act is set out in '**Annexure B**' to this Notice. Mr. Rajaram Narayanan satisfies all the conditions set out in Part-I of Schedule V and Section 196(3) of the Act for being eligible for this appointment.

The Company has not committed any default in payment of dues to any bank or public financial institution or non-convertible debenture holders or any other secured creditor, if any.

The Board recommends the Special Resolution as set out in **Item No. 3** for approval by the Members.

Except Mr. Rajaram Narayanan and/or his relatives, none of the other Directors, Key Managerial Personnel or their relatives are concerned or interested in this Resolution.

Item No. 4: Appointment of Mr. Srinivas Vasireddy (DIN: 09771153) as a Whole time Director (Executive) of the Company for a period of two years.

The Board, based on the recommendation of NRC, at its meeting held on December 16, 2025, has appointed Mr. Srinivas Vasireddy (DIN: 09771153) as a Whole-time Director (Executive, Non-independent) of the Company for a period of 2 years, w.e.f December 16, 2025, to December 15, 2027, liable to retire by rotation, subject to the approval of the Members.

The Company has received the following from Mr. Vasireddy:

- (i) the consent in writing to act as an Executive Director of the Company.
- (ii) intimation that he is not disqualified under section 164(2) of the Act or debarred pursuant to any order of SEBI, Ministry of Corporate Affairs or any such other Authority.
- (iii) disclosure of interest in other entities in terms of Section 184(1) of the Act.

The Company has received a notice from a Member, under Section 160 of the Act, proposing candidature of Mr. Vasireddy as Whole time Director.

The Members are informed, the Board at its meeting held on December 16, 2025, had pursuant to the recommendation of the NRC, approved the remuneration payable to Mr. Srinivas Vasireddy, Whole time Director of the Company for the period starting from December 16, 2025, to December 15, 2027, as detailed below:

Sr. No.	Particulars	Amount per annum (in INR)
1	Basic Salary (1)	80,65,675
2	Other allowances (2)	80,65,675
3	Fixed remuneration (1+2)	1,61,31,350
4	Variable pay (Performance bonus)	49,34,812
5	Total remuneration (Fixed + Variable)	2,10,66,162
6	Retirals	13,55,654
7	Other benefits (Company car for business use, Housing/ HRA, Leave encashment, Insurance Medical, Reimbursements etc.)	As per Company's Policy
8	Employee Stock Option Plan	As per may be determined by the NRC and Board in accordance with the Viyash Scientific Limited Employee Stock Option Scheme 2026.

The above remuneration shall be subject to an annual increment of up to 20% of his total remuneration, based on the recommendation of the NRC and approval of the Board, in accordance with the agreed performance criteria.

Further, Mr. Vasireddy shall not be entitled to sitting fees for attending meetings of the Board of Directors of the Company or any Committee(s) thereof.

The proposed remuneration for Mr. Vasireddy has been set based on a benchmarking process against a peer group of leading and well-governed companies in the industry. The remuneration structure is designed to align with market standards and ensure competitiveness.

Additional information in respect of Mr. Vasireddy, pursuant to Regulation 36 of the SEBI Listing Regulations and the Secretarial Standards on General Meetings ('Secretarial Standards – 2') issued by The Institute of Company Secretaries of India, is provided in '**Annexure A**' and forms an integral part of this Notice. Further, disclosure under Schedule V of the Companies Act, 2013 is set out in '**Annexure B**' to this Notice.

The Company has not committed any default in payment of dues to any bank or public financial institution or non-convertible debenture holders or any other secured creditor, if any.

The Board recommends the Special Resolution as set out in **Item No. 4** for approval by the Members.

Except Mr. Srinivas Vasireddy and/or his relatives, none of the other Directors, Key Managerial Personnel or their relatives are concerned or interested in this Resolution.

**By order of the Board of Directors of
Viyash Scientific Limited
(Formerly known as Sequent Scientific Limited)**

Place: Hyderabad
Date : February 5, 2026

**Sd/-
Yoshita Vora
Company Secretary & Compliance officer
Membership No.: ACS 22220**

ANNEXURE – A

Relevant details pursuant to Regulation 36(3) of the Listing Regulations and Secretarial Standard on General Meetings issued by Institute of Company Secretaries of India, is as given under:

Details of Dr. Haribabu Bodepudi, Managing Director and Group CEO of the Company:

Name of the Director	Dr. Haribabu Bodepudi
DIN	01119687
Age	61
Nationality	Indian
Date of first appointment on the Board	August 7, 2023
Brief resume, Qualification(s), Experience and Nature of expertise in specific function	<p>Dr. Haribabu Bodepudi holds a PhD degree in Organic Chemistry from Andhra University and has over 30 years of Industry experience permeating diverse roles in Research, Manufacturing, Quality and operations in both APIs and Oral Solids.</p> <p>During the last 20 years, he held several leadership roles in technical and commercial operations in Mylan Laboratories, including being the COO of Mylan India, CEO of Mylan India and the Global COO of Mylan.</p> <p>He was responsible for more than 50 Mylan facilities and managing more than 200 APIs and 15000 SKUs of different formulations.</p> <p>At Mylan, he led Mylan's foray into the ARV business and grew that business to over USD800 Million with global leadership (in volume, value and portfolio spread) and more than 50% market share.</p> <p>He has hands-on experience in global supply chain, regulatory, API R&D, quality and Commercial operations.</p>
Terms and conditions of appointment or Reappointment	<ul style="list-style-type: none"> • Executive Non-Independent Director, Liable to retire by rotation. • Tenure: December 16, 2025, to December 15, 2027
Shareholding in Viyash Scientific Limited including shareholding as a beneficial owner as at the date of notice	1,20,99,324 equity shares held in Viyash Scientific Limited.
Details of remuneration sought to be paid and the remuneration last drawn.	<p>Dr. Haribabu being an erstwhile Non-executive Director in the company was entitled sitting fees for attending meetings of the Board or Committees thereof, reimbursement of expenses for participating in the Board and other meetings and was eligible for commission as approved by the Board and Shareholders from time to time.</p> <p>Remuneration sought to be paid is as per explanatory statement against Item No.3 to this notice read with Annexure B thereto.</p>
Relationship with other directors, Managers and Key Managerial Personnel of the Company	None
Number of Board & Committee Meetings attended during the FY 2025-26	7 of 7
Membership/Chairmanship of the Committees of Viyash Scientific Limited	<p>Memberships:</p> <ul style="list-style-type: none"> • Risk Management Committee • Corporate Social Responsibility Committee • Stakeholders Relationship Committee
List of Directorships held in Other Companies	Nil
Listed entities from which the appointee has resigned in the past 3 years:	Nil

Details of Mr. Rajaram Narayanan, Wholetime Director and CEO- Animal Health Business of the Company:

Name of the Director	Mr. Rajaram Narayanan
DIN	02977405
Age	57
Nationality	Indian
Date of first appointment on the Board	April 11, 2022
Brief resume, Qualification(s), Experience and Nature of expertise in specific function	<p>With over 25 years of experience, Mr. Narayanan has a strong track record of leading revenue and profitability growth across multiple industries including pharmaceuticals. He joined from Sanofi India Limited, where he was the Managing Director and Country Chair for India.</p> <p>At Sanofi, he led the strategic reorientation of its India business operations, resulting in accelerated growth in key therapies and significant transformation of Sanofi's market operations.</p> <p>Before Sanofi, he was Chief Marketing Officer at Airtel, India's leading telecommunications company. Mr. Narayanan started his career at Hindustan Unilever Ltd., where he held various leadership roles in India and other Asian markets for over 18 years, building and managing many iconic consumer brands.</p>
Terms and conditions of appointment or Reappointment	<ul style="list-style-type: none"> Executive Non-Independent Director, liable to retire by rotation. Tenure: Up to April 11, 2027.
Shareholding in Viyash Scientific Limited including shareholding as a beneficial owner as at the date of notice	18,34,735 equity shares held in Viyash Scientific Limited.
Details of remuneration sought to be paid and the remuneration last drawn.	Please refer explanatory statement against Item No.3 to this notice read with Annexure B to this notice.
Relationship with other directors, Managers and Key Managerial Personnel of the Company	None
Number of Board & Committee Meetings attended during the FY 2025-26	7 of 7
Membership/Chairmanship of the Committees of Viyash Scientific Limited	<p>Memberships:</p> <ul style="list-style-type: none"> Risk Management Committee Corporate Social Responsibility Committee Stakeholders Relationship Committee
List of Directorships held in Other Companies	<ul style="list-style-type: none"> Alivira Animal Health Limited Topkim Topkapi ilac Premiks Sanayi Ve Ticaret Anonik Sirketi Provet Veterinary Ürünleri San. Ve Tic. A. Ş. Vila Viña Participacions S.L. Laboratorios Karizoo, S.A
Membership/ Chairmanship of Committees of other Companies	<ul style="list-style-type: none"> Memberships: <ul style="list-style-type: none"> Alivira Animal Health Limited (Corporate Social Responsibility Committee) Chairmanships: <ul style="list-style-type: none"> Alivira Animal Health Limited (Banking Committee)
Listed entities from which the appointee has resigned in the past 3 years:	Nil

Details of Mr. Srinivas Vasireddy, Wholetime Director of the Company:

Name of the Director	Mr Srinivas Vasireddy
DIN	09771153
Age	57
Nationality	Indian
Date of first appointment on the Board	December 16, 2025
Brief resume, Qualification(s), Experience and Nature of expertise in specific function	<p>Mr. Vasireddy brings with him 37 years of extensive experience across all facets of API operations. His core expertise spans Manufacturing, Production Planning & Inventory Control (PPIC), Third-Party Manufacturing, and leading initiatives in Quality improvement, regulatory Compliance, and EHS enhancements.</p> <p>He was associated with the Viyash Lifesciences Private Limited, where he oversees overall API operations across all units. Prior to this, he served as the Head of API (Special Projects) at Mylan Laboratories, contributing significantly to strategic and operational advancements in the API domain.</p> <p>Mr. Vasireddy holds a Bachelor of Science degree from Nagarjuna University, providing a strong academic foundation for his long-standing professional journey.</p>
Terms and conditions of appointment or Reappointment	<ul style="list-style-type: none">• Executive Non-Independent Director, liable to retire by rotation.• Tenure: December 16, 2025, to December 15, 2027
Shareholding in Viyash Scientific Limited including shareholding as a beneficial owner as at the date of notice	35,000 equity shares held in Viyash Scientific Limited.
Relationship with other directors, Managers and Key Managerial Personnel of the Company	None
Details of remuneration sought to be paid and the remuneration last drawn.	Please refer explanatory statement against Item No.4 to this notice read with Annexure B thereto.
Number of Board & Committee Meetings attended during the FY 2025-26	Nil
Membership/Chairmanship of the Committees of Viyash Scientific Limited	Nil
List of Directorships held in Other Companies	<ul style="list-style-type: none">• Alivira Animal Health Limited
Membership/ Chairmanship of Committees of other Companies	Nil
Listed entities from which the appointee has resigned in the past 3 years:	Nil

ANNEXURE – B

STATEMENT PURSUANT TO PART II OF SCHEDULE V TO THE COMPANIES ACT, 2013 IN RESPECT OF ITEM NOS. 1 to 4 OF THE NOTICE

1. General Information:

a. Nature of Industry:

The Company operates in the pharmaceutical and life sciences industry, specializing in the development and manufacturing of niche formulations, Active Pharmaceutical Ingredients (APIs), and advanced intermediates. With capabilities spanning API production, formulation manufacturing, and extensive R&D, the Company serves regulated and semi-regulated markets across multiple therapeutic areas. Its focus on high-quality, cost-efficient pharmaceutical solutions positions it as a key player supporting global healthcare needs.

b. Date or expected date of Commencement of Commercial production:

Not applicable as the Company is an existing Company

c. In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus:

Not Applicable as the Company is an existing Company

d. Financial performance based on given indicators of the Company:

Particulars	Rs. In Million			
	Year to date for the period ended December 31, 2025 (Unaudited)*	For the year ended March 31, 2025 (Audited)	For the year ended March 31, 2024 (Audited)	For the year ended March 31, 2023 (Audited)
Total income	10,560.80	2291.94	2144.98	2509.27
Profit / (Loss) before tax	674.70	220.48	(2.39)	(97.46)
Profit / (Loss) after tax	400.60	157.94	6.22	(60.80)

* Post merger after effectiveness of the Composite Scheme of Amalgamation

e. Foreign Investment or collaborations, if any:

The foreign investment in the Company is 58.40% of the Paid-up Share Capital of the Company as on December 31, 2025. The Company does not have any foreign collaborations.

2. Information about the appointee

a. Background details:

i. Brief profile of Dr. Haribabu Bodepudi:

Dr. Haribabu Bodepudi holds a PhD degree in Organic Chemistry from Andhra University and has over 30 years of Industry experience permeating diverse roles in Research, Manufacturing, Quality and operations in both APIs and Oral Solids. During the last 20 years, he held several leadership roles in technical and commercial operations in Mylan Laboratories, including being the COO of Mylan India, CEO of Mylan India and the Global COO of Mylan.

He was responsible for more than 50 Mylan facilities and managing more than 200 APIs and 15000 SKUs of different formulations. At Mylan, he led Mylan's foray into the ARV business and grew that business to over USD800 Million with global leadership (in volume, value and portfolio spread) and more than 50% market share.

He has hands-on experience in global supply chain, regulatory, API R&D, quality and Commercial operations.

ii. Brief profile of Mr. Rajaram Narayan:

With over 25 years of experience, Mr. Narayanan has a strong track record of leading revenue and profitability growth across multiple industries including pharmaceuticals. He joined from Sanofi India Limited, where he was the Managing Director and Country Chair for India.

At Sanofi, he led the strategic reorientation of its India business operations, resulting in accelerated growth in key therapies and significant transformation of Sanofi's market operations.

Before Sanofi, he was Chief Marketing Officer at Airtel, India's leading telecommunications company. Mr. Narayanan started his career at Hindustan Unilever Ltd., where he held various leadership roles in India and other Asian markets for over 18 years, building and managing many iconic consumer brands.

iii. Brief profile of Mr. Srinivas Vasireddy:

Mr. Vasireddy brings with him 37 years of extensive experience across all facets of API operations. His core expertise spans Manufacturing, Production Planning & Inventory Control (PPIC), Third-Party Manufacturing, and leading initiatives in Quality improvement, regulatory Compliance, and EHS enhancements.

He was associated with the Viyash Lifesciences Private Limited, where he oversees overall API operations across all units. Prior to this, he served as the Head of API (Special Projects) at Mylan Laboratories, contributing significantly to strategic and operational advancements in the API domain.

Mr. Vasireddy holds a Bachelor of Science degree from Nagarjuna University, providing a strong academic foundation for his long-standing professional journey.

b. Past remuneration, Recognition and rewards:

i. Dr. Haribabu Bodepudi

Dr. Haribabu Bodepudi being a non-executive director of the Company was entitled to sitting fees and commission as approved by Board and shareholders from time to time.

ii. Mr. Rajaram Narayanan

In the financial year 2024-25, remuneration of Mr. Rajaram Narayanan was Rs.19.87 Million from the Company. Further, he had additionally received remuneration of Rs.29.36 Million from Alivira Animal Health Limited, a wholly owned subsidiary of the Company. Remuneration of Mr. Rajaram Narayanan for the past year was approved via special resolution passed by the shareholders of the Company. For reference, the remuneration terms approved by the Members for Mr. Rajaram are available at [Sequent Annual-Report-FY-2024-25](#)

iii. Mr. Srinivas Vasireddy

Mr. Srinivas Vasireddy being a new appointee to the Board, did not receive any remuneration from the Company.

c. Job Profile and suitability:

i. Dr. Haribabu Bodepudi

Considering Dr. Haribabu Bodepudi's distinguished career spanning more than three decades across research, manufacturing, quality, and large-scale operations in both APIs and formulations, the Board is confident that his comprehensive industry insight and proven capability in steering complex, globally regulated businesses will shape the Company's forward trajectory. His strategic acumen, coupled with his hands-on leadership of extensive global supply chains, multi-site operations and high-value portfolios, positions him to drive the Company's next chapter of sustainable growth and operational excellence.

ii. Mr. Rajaram Narayanan:

Considering Mr. Rajaram Narayanan's solid track record of successfully transforming businesses in highly complex and regulated industries, the Board believes that his strategic vision as well as operational expertise and rigor will be pivotal for the Company's next phase of growth and success.

iii. Mr. Srinivas Vasireddy

Given Mr. Srinivas Vasireddy's extensive experience in API operations, strong leadership in manufacturing and quality systems, and his proven ability to drive operational excellence across multiple units, the Board considers him well-suited for the role of Wholetime Director of the Company.

d. Remuneration proposed:

As provided in Item No. 1 & 2 of the Explanatory Statement to this Notice for Dr. Haribabu Bodepudi, Item No. 3 of the Explanatory Statement to this Notice for Mr. Rajaram Narayan, and Item No. 4 of the Explanatory Statement for Mr. Srinivas Vasireddy.

e. Comparative remuneration profile with respect to industry, size of the company, profile of the position and person:

The remuneration payable to Dr. Haribabu Bodepudi, Mr. Rajaram Narayanan and Mr. Srinivas Vasireddy has been benchmarked with the remuneration being drawn by other managerial personnel in the similar capacity of other Companies of comparable size in the pharmaceutical industry. Considering the general industry and the specific Company profile, the remuneration is in line with the industry levels and that of comparatively placed companies in India.

f. Pecuniary relationship directly or indirectly with the company or relationship with the managerial personnel or other directors, if any:

Dr. Haribabu Bodepudi, Mr. Rajaram Narayanan and Mr. Srinivas Vasireddy have no other pecuniary relationship with the Company except to the extent of their respective remuneration and shareholding in the Company.

3. Other Information:

Reasons of loss or inadequate profits, steps taken or proposed to be taken for improvement and expected increase in productivity and profits in measurable terms:

The Company is proactively implementing strategic initiatives aimed at enhancing future performance. Efforts are underway to drive organizational and operational efficiencies, reinforce core competencies, and strengthen financial resilience. Key focus areas include profit optimization, prudent cash management, improved operational execution, and effective cost and working capital control.

The Company is focused on growth by expanding into new markets and increasing its international presence. It is also accelerating research and development in our businesses to create future pipeline on new products to drive consistent growth.